AMAG - AMAG Pharmaceuticals, Inc.
| Previous Close | 11.84 |
| Open | 11.71 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 1100 |
| Day's Range | 11.11 - 11.89 |
| 52 Week Range | 6.81 - 17.25 |
| Volume | 1,332,668 |
| Avg. Volume | 818,587 |
| Market Cap | 389.693M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG
Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether AMAG and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG
NEW YORK, NY / ACCESSWIRE / January 14, 2020 / Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether AMAG and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- ACCESSWIRE
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. (AMAG)
NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AMAG Pharmaceuticals, Inc. ("AMAG" or the Company") ...
- GlobeNewswire
AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update
AMAG Pharmaceuticals, Inc. (AMAG) today announced the initiation of a leadership transition, the decision to divest Intrarosa and Vyleesi and financial updates. AMAG announced that William Heiden plans to step down as AMAG’s President and Chief Executive Officer, and that the Company’s Board of Directors will immediately initiate a search for his successor, which it expects to complete by mid-2020. The Company has received preliminary expressions of interest to acquire/sub-license the rights to these products.
- GlobeNewswire
AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2020 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference on.
- GlobeNewswire
AMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia Research
As part of the company’s ongoing support of research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (AMAG) today announced it has awarded four grants totaling nearly $300,000 to independent researchers in the field. “Preterm birth is the leading cause of infant morbidity and mortality, and over the past few years the March of Dimes report card has shown that U.S. preterm birth rates have risen,” said Brian Robinson, M.D., senior vice president of medical affairs at AMAG. The panel was chaired by George Saade, M.D., Professor, Obstetrics/Gynecology and Cell Biology at The University of Texas Medical Branch.
- GlobeNewswire
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 13, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:.
- GlobeNewswire
AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update
Commercial products achieve strong revenue and market share performance Vyleesi™ (bremelanotide injection) launched nationally in September Committed to work with the FDA to.
- GlobeNewswire
AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)
AMAG Pharmaceuticals, Inc. (AMAG) today announced the U.S. Food and Drug Administration’s (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to better understand and interpret the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) confirmatory clinical trial for Makena® (hydroxyprogesterone caproate injection), a treatment approved to reduce preterm birth in pregnant women who have had a prior spontaneous preterm birth. While the committee discussed multiple questions, in a mixed vote on the key question, nine advisory committee members voted to recommend that the FDA pursue withdrawal of approval for Makena and seven committee members voted to leave the product on the market under accelerated approval and require a new confirmatory trial.
- GlobeNewswire
AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial
WALTHAM, Mass., Oct. 29, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug.
- GlobeNewswire
AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the results of PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) were published online in the American Journal of Perinatology. PROLONG was a randomized, double-blind, placebo-controlled clinical trial evaluating 17-OHPC (17-α-hydroxyprogesterone caproate or Makena®) in patients with a history of a prior spontaneous singleton preterm delivery. As previously announced, the PROLONG trial did not meet the two pre-specified co-primary endpoints of a reduction of preterm birth (defined as less than 35 weeks of gestation) and a reduction in the neonatal morbidity and mortality index, in contrast to the original Meis trial results published in the New England Journal of Medicine.
- GlobeNewswire
AMAG Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Friday, November 1, 2019 at 8:00 a.m. ET
WALTHAM, Mass., Oct. 24, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2019 financial results will be released on Friday, November 1,.
- GlobeNewswire
AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ (Bremelanotide Injection) Data in Obstetrics & Gynecology
AMAG Pharmaceuticals, Inc. (AMAG) announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and its voluntary open-label one year extension studies were published in Obstetrics & Gynecology (the Green Journal). These publications are currently available online and will appear in the November print issue. In both randomized placebo-controlled clinical trials, Vyleesi™ (bremelanotide injection) met the pre-specified co-primary efficacy endpoints of improvement in desire and reduction in associated distress as measured by validated patient-reported outcome instruments. The RECONNECT data from approximately 1,200 women was the basis for the June 2019 U.S. Food and Drug Administration approval of Vyleesi, the first and only as-needed treatment for premenopausal women with acquired, generalized HSDD.
- GlobeNewswire
AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP
AMAG Pharmaceuticals, Inc. (AMAG) (“AMAG”) today announced that it has entered into a settlement agreement with Caligan Partners LP (“Caligan”). As part of this agreement, the Board of Directors has appointed Paul Fonteyne, former Chief Executive Officer of Boehringer Ingelheim USA, and David Johnson, Partner and co-Founder of Caligan, to the AMAG Board, effective immediately.
- GlobeNewswire
AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
WALTHAM, Mass., Sept. 25, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday,.
- GlobeNewswire
AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
AMAG Pharmaceuticals, Inc. (AMAG) (“AMAG” or the “Company”) today announced that it filed a definitive consent revocation statement with the U.S. Securities and Exchange Commission on September 20, 2019, and has sent a letter to AMAG shareholders. The letter contains AMAG’s response to the consent solicitation made by Caligan Partners LP (“Caligan”), including AMAG’s thoughts on Caligan’s director nominees and Caligan’s views on the Company’s business and strategy. AMAG urges shareholders to sign and return AMAG’s GREEN Consent Revocation Card and disregard any white consent cards received from Caligan.
- GlobeNewswire
AMAG Sends Letter to Shareholders
WALTHAM, Mass., Sept. 12, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today issued the following letter, which will be mailed to its.